Conatus Pharmaceuticals (NASDAQ:CNAT)

CAPS Rating: 3 out of 5

Results 1 - 9 of 9

Recs

1
Member Avatar TSIF (99.96) Submitted: 1/19/2016 3:40:42 PM : Outperform Start Price: $1.47 CNAT Score: +13.66

Bantered this one around with vchelimella yesterday on an unrelated thread.

Stuck a fork in it after another large Biotech sell. High risk, not recommending, but peaked my interest enough to watch.

No target. A serious bounce would either indicate a bank or a reason to ride, but with Phase III data out in forever land this is probably not a hold.

===================================

Biotech: Biotechs with no approved drugs are always high risk. The risk on / risk off really hammers them in this type of market. While I think Biotechs in general are a better play than oil, and may be hitting a bottom, (no idea if short term or long term), I would be very selective. They should have enough cash on their books to fund operations at their current burn rate for at least 18 months and two years preferably. CNAT fits this requirement. I don't know much about their one trick pony and Phase II data didn't give it a boost last week. The 2B is starting and this type of drug requires a long year or more test. So no news is likely in 2016 to influence it. From a technical standpoint it is due a bounce, maybe as high as $4, but it needs a catalyst I don't see happening unless they can coheres a partner. Generally sub $200M market cap biopharm aren't good bets. If they had something that might have value, someone would partner with them.

CNAT getting past the initial safety testing after the drug was dropped by Pfizer might make it a longer term hold for a highly risk tolerate, patent investor. It appears that they got the large spike after Phase IIa by implying they might be able to skip to Phase III. Now they are saying a year and a half in phase II, so the patient people are gone. Most investors don't want to be in biopharms until they are in the late Phase III with talks of FDA meetings/potential.

If it is undersold now it might make a bounce and hold it.

Recs

0
Member Avatar oscillation (26.80) Submitted: 1/16/2016 11:28:48 AM : Outperform Start Price: $1.70 CNAT Score: +0.04

nev

Recs

0
Member Avatar Hendrickson71 (< 20) Submitted: 9/25/2015 11:31:29 AM : Outperform Start Price: $5.76 CNAT Score: -65.37

still has a target price of $14

Recs

0
Member Avatar km00nster (< 20) Submitted: 3/26/2015 3:05:36 PM : Outperform Start Price: $6.89 CNAT Score: -65.10

Excellent news today! Should hit 12 dollars by the end of the year.

Recs

0
Member Avatar joienpaix (< 20) Submitted: 3/13/2015 4:39:05 PM : Outperform Start Price: $5.69 CNAT Score: -59.43

jeepdrew2 TP 8

Recs

1
Member Avatar OKwarrior (20.08) Submitted: 11/9/2014 5:37:27 PM : Outperform Start Price: $6.89 CNAT Score: -65.86

small biopharma company specializing in development of drugs for liver disease (think Gilead). They have ongoing trials for 5 different diseases, NASH, acute on chronic liver failure, portal hypertension, post transplant liver fibrosis w. clearance of Hep C

Recs

0
Member Avatar aki92656 (44.12) Submitted: 3/31/2014 4:10:53 PM : Outperform Start Price: $8.05 CNAT Score: -77.24

20140331 started at 8.20

Recs

0
Member Avatar usubanas (99.71) Submitted: 3/25/2014 3:29:16 PM : Outperform Start Price: $9.35 CNAT Score: -80.31

Phase 2 NAFLD/NASH trial results expected 2nd half 2014. At 145M, great risk reward.

Recs

1
Member Avatar sinvestor (67.04) Submitted: 1/14/2014 6:36:43 AM : Underperform Start Price: $12.16 CNAT Score: +86.48

Really???

Results 1 - 9 of 9

Featured Broker Partners